JP2020530446A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530446A5 JP2020530446A5 JP2020505383A JP2020505383A JP2020530446A5 JP 2020530446 A5 JP2020530446 A5 JP 2020530446A5 JP 2020505383 A JP2020505383 A JP 2020505383A JP 2020505383 A JP2020505383 A JP 2020505383A JP 2020530446 A5 JP2020530446 A5 JP 2020530446A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- alkyl
- optionally substituted
- compound according
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022211691A JP2023052166A (ja) | 2017-08-09 | 2022-12-28 | 化合物、組成物、及び、方法 |
| JP2024223976A JP2025031810A (ja) | 2017-08-09 | 2024-12-19 | 化合物、組成物、及び、方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762543307P | 2017-08-09 | 2017-08-09 | |
| US62/543,307 | 2017-08-09 | ||
| US201762553728P | 2017-09-01 | 2017-09-01 | |
| US62/553,728 | 2017-09-01 | ||
| US201762608504P | 2017-12-20 | 2017-12-20 | |
| US62/608,504 | 2017-12-20 | ||
| PCT/US2018/045868 WO2019032743A1 (en) | 2017-08-09 | 2018-08-08 | COMPOUNDS, COMPOSITIONS AND METHODS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211691A Division JP2023052166A (ja) | 2017-08-09 | 2022-12-28 | 化合物、組成物、及び、方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020530446A JP2020530446A (ja) | 2020-10-22 |
| JP2020530446A5 true JP2020530446A5 (enExample) | 2021-09-16 |
Family
ID=65272557
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505383A Withdrawn JP2020530446A (ja) | 2017-08-09 | 2018-08-08 | 化合物、組成物、及び、方法 |
| JP2022211691A Withdrawn JP2023052166A (ja) | 2017-08-09 | 2022-12-28 | 化合物、組成物、及び、方法 |
| JP2024223976A Pending JP2025031810A (ja) | 2017-08-09 | 2024-12-19 | 化合物、組成物、及び、方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211691A Withdrawn JP2023052166A (ja) | 2017-08-09 | 2022-12-28 | 化合物、組成物、及び、方法 |
| JP2024223976A Pending JP2025031810A (ja) | 2017-08-09 | 2024-12-19 | 化合物、組成物、及び、方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11236100B2 (enExample) |
| EP (1) | EP3665156A4 (enExample) |
| JP (3) | JP2020530446A (enExample) |
| KR (2) | KR102757890B1 (enExample) |
| CN (3) | CN118239937A (enExample) |
| AU (3) | AU2018313850B2 (enExample) |
| CA (1) | CA3071024A1 (enExample) |
| CL (1) | CL2020000299A1 (enExample) |
| CO (1) | CO2020001220A2 (enExample) |
| CR (1) | CR20200054A (enExample) |
| IL (2) | IL272089B2 (enExample) |
| MA (1) | MA49858A (enExample) |
| MX (2) | MX2020001352A (enExample) |
| MY (1) | MY201438A (enExample) |
| PE (1) | PE20200834A1 (enExample) |
| PH (1) | PH12020550028B1 (enExample) |
| SA (1) | SA520411222B1 (enExample) |
| SG (1) | SG11202000532SA (enExample) |
| TW (1) | TW201920115A (enExample) |
| WO (1) | WO2019032743A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3634952A1 (en) * | 2017-06-07 | 2020-04-15 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| CR20200054A (es) | 2017-08-09 | 2020-03-21 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| HUE062446T2 (hu) | 2017-09-01 | 2023-11-28 | Denali Therapeutics Inc | Vegyületek, készítmények és eljárások |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| JP2021501785A (ja) | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| AU2018383675A1 (en) | 2017-12-13 | 2020-07-09 | Altos Labs, Inc. | Inhibitors of integrated stress response pathway |
| MX2020013269A (es) | 2018-06-05 | 2021-02-18 | Praxis Biotech LLC | Inhibidores de la vía de respuesta al estrés integrada. |
| TWI771621B (zh) | 2018-10-11 | 2022-07-21 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| MA54959A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| EP3923935A4 (en) | 2019-02-13 | 2022-10-26 | Denali Therapeutics Inc. | COMPOUNDS, COMPOSITIONS AND METHODS |
| IL287379B2 (en) | 2019-04-23 | 2025-11-01 | Evotec Int Gmbh | Modulators of the integrated stress response pathway |
| CA3137212A1 (en) | 2019-04-23 | 2020-10-29 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| PE20220572A1 (es) * | 2019-04-30 | 2022-04-20 | Calico Life Sciences Llc | Moduladores de la via integrada del estres |
| CN114466654A (zh) | 2019-06-12 | 2022-05-10 | 普拉西斯生物技术有限责任公司 | 整合应激反应通路调节剂 |
| EP4096665A1 (en) | 2020-01-28 | 2022-12-07 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| CA3165813A1 (en) * | 2020-03-11 | 2021-09-16 | Holly Victoria Atton | Modulators of the integrated stress response pathway |
| AU2021363616B2 (en) * | 2020-10-22 | 2026-03-26 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| KR20230110509A (ko) | 2020-10-22 | 2023-07-24 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절제 |
| MX2023004626A (es) | 2020-10-22 | 2023-05-23 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| KR20230116796A (ko) * | 2020-10-30 | 2023-08-04 | 칼리코 라이프 사이언시스 엘엘씨 | 통합된 스트레스 경로의 조절인자 |
| CN117580824A (zh) * | 2020-10-30 | 2024-02-20 | 卡里科生命科学有限责任公司 | 整合应激通路的调节剂 |
| CN116507608A (zh) * | 2020-11-20 | 2023-07-28 | 戴纳立制药公司 | 化合物、组合物和方法 |
| EP4251622A1 (en) * | 2020-11-25 | 2023-10-04 | F. Hoffmann-La Roche AG | Aromatic bridged ring amide derivatives for the treatment and prophylaxis of hepatitis b virus infection |
| US20240059662A1 (en) * | 2020-12-18 | 2024-02-22 | Denali Therapeutics Inc. | Solid forms of a compound |
| JP2025523444A (ja) * | 2022-06-23 | 2025-07-23 | デナリ セラピューティクス インコーポレイテッド | 真核生物型開始因子２ｂのモジュレーターの調製プロセス |
| WO2024109736A1 (zh) * | 2022-11-21 | 2024-05-30 | 深圳众格生物科技有限公司 | 一种化合物、包含其的药物组合物及其合成方法和用途 |
| WO2025019827A1 (en) * | 2023-07-20 | 2025-01-23 | Denali Therapeutics Inc. | Formulation, solid dosage form, and methods |
| WO2025230528A1 (en) * | 2024-05-01 | 2025-11-06 | Calico Life Sciences Llc | Methods of treating amyotrophic lateral sclerosis |
| WO2026004939A1 (ja) * | 2024-06-28 | 2026-01-02 | キッセイ薬品工業株式会社 | ジ置換ビシクロ［１．１．１］ペンタン化合物 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6429207B1 (en) | 1997-11-21 | 2002-08-06 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| AU762345B2 (en) | 1998-10-16 | 2003-06-26 | Asubio Pharma Co., Ltd. | Aminophenoxyacetic acid derivatives as neuroprotectants |
| AR024077A1 (es) | 1999-05-25 | 2002-09-04 | Smithkline Beecham Corp | Compuestos antibacterianos |
| US20010047100A1 (en) | 2000-04-26 | 2001-11-29 | Kjaersgaard Hans Joergen | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives |
| US7259157B2 (en) | 2001-04-03 | 2007-08-21 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists |
| JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| WO2006028904A1 (en) | 2004-09-02 | 2006-03-16 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| WO2006125974A1 (en) | 2005-05-24 | 2006-11-30 | Astrazeneca Ab | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| DK1966130T3 (da) | 2005-12-23 | 2014-02-10 | Zealand Pharma As | Modificerede lysin-mimetiske forbindelser |
| MX2009004089A (es) | 2006-10-20 | 2009-07-10 | Arete Therapeutics Inc | Inhibidores de epoxido hidrolasa soluble. |
| CN101711243B (zh) | 2007-06-15 | 2013-01-09 | 埃科特莱茵药品有限公司 | 3-氨基-6-(1-氨基-乙基)-四氢吡喃衍生物 |
| CN102232078B (zh) | 2008-12-12 | 2014-07-16 | 埃科特莱茵药品有限公司 | 5-氨基-2-(1-羟基-乙基)-四氢吡喃衍生物 |
| US9421211B2 (en) | 2009-05-28 | 2016-08-23 | President And Fellows Of Harvard College | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation |
| DK2442809T3 (en) | 2009-06-17 | 2016-12-19 | Vertex Pharma | Inhibitors of the replication of influenza virus |
| AR084457A1 (es) | 2010-12-22 | 2013-05-15 | Lundbeck & Co As H | Derivados de biciclo[3,2,1]octilamida |
| WO2012113774A1 (en) | 2011-02-24 | 2012-08-30 | Nerviano Medical Sciences S.R.L. | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
| DK2684880T3 (en) | 2011-03-10 | 2018-05-22 | Daiichi Sankyo Co Ltd | DISPIROPYRROLIDINE DERIVATIVES |
| HRP20240097T1 (hr) * | 2011-04-22 | 2024-03-29 | Signal Pharmaceuticals, Llc | Supstituirani diaminokarboksamid i diaminokarbonitril pirimidini, njihovi pripravci i postupci liječenja s njima |
| WO2013120940A2 (en) | 2012-02-14 | 2013-08-22 | Syngenta Participations Ag | Novel compounds |
| JPWO2014054635A1 (ja) | 2012-10-02 | 2016-08-25 | 大日本住友製薬株式会社 | イミダゾール誘導体 |
| US9447025B2 (en) | 2013-03-14 | 2016-09-20 | Kalyra Pharmaceuticals, Inc. | Bicyclic analgesic compounds |
| JP6806562B2 (ja) | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｅＩＦ２α経路の調節因子 |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20160318856A1 (en) | 2013-09-11 | 2016-11-03 | The Brigham And Women's Hospital, Inc. | Substituted Urea eIF2alpha Kinase Activators |
| RU2016141934A (ru) * | 2014-04-04 | 2018-05-07 | Сирос Фармасьютикалз, Инк. | Ингибиторы циклин-зависимой киназы 7 (cdk7) |
| CN106999451B (zh) * | 2014-09-17 | 2021-04-02 | 里科瑞尔姆Ip控股有限责任公司 | 双环化合物 |
| ES2772133T3 (es) * | 2014-11-20 | 2020-07-07 | Merck Patent Gmbh | Compuestos heteroarilo como inhibidores de IRAK y sus usos |
| EP3623371A1 (en) | 2014-12-16 | 2020-03-18 | Axovant Sciences GmbH | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
| EA201791896A1 (ru) | 2015-02-25 | 2018-02-28 | Уильям Марш Райс Юниверсити | Дезацетокситубулизин н и его аналоги |
| GB201506894D0 (en) | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| MX2017014222A (es) | 2015-05-05 | 2018-08-15 | Bayer Pharma AG | Derivados de ciclohexano sustituido con amido. |
| TW201718557A (zh) | 2015-10-08 | 2017-06-01 | 歌林達有限公司 | 經吡唑基取代之四氫吡喃基碸 |
| TW201808914A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TWI763668B (zh) * | 2016-05-05 | 2022-05-11 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808888A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| KR20190015492A (ko) | 2016-06-08 | 2019-02-13 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 화학적 화합물 |
| KR20190015748A (ko) | 2016-06-08 | 2019-02-14 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Atf4 경로 억제제로서의 화학적 화합물 |
| BR112019000201A2 (pt) * | 2016-07-06 | 2019-07-09 | Acquist Llc | compostos e seu uso na redução dos níveis de ácido úrico |
| JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| BR112019011801A2 (pt) | 2016-12-08 | 2019-10-29 | Univ Texas | composto, composição farmacêutica e método de inibição de dlk, método de tratamento de uma doença mediada por dlk, método de tratamento de câncer e redução do desenvolvimento de um distúrbio neurológico induzido por quimioterapia e método para alcançar um efeito em um paciente |
| WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| EP3634952A1 (en) * | 2017-06-07 | 2020-04-15 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| CA3068395A1 (en) | 2017-07-03 | 2019-01-10 | Glaxosmithkline Intellectual Property Development Limited | 2-(4-chlorophenoxy)-n-((1-(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| CA3068753A1 (en) | 2017-07-03 | 2019-01-10 | Glaxosmithkline Intellectual Property Development Limited | N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| CR20200054A (es) | 2017-08-09 | 2020-03-21 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| HUE062446T2 (hu) | 2017-09-01 | 2023-11-28 | Denali Therapeutics Inc | Vegyületek, készítmények és eljárások |
| WO2019054430A1 (ja) | 2017-09-14 | 2019-03-21 | 第一三共株式会社 | 芳香族複素環を有するアミド化合物 |
| EP3704089B1 (en) | 2017-11-02 | 2023-07-19 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
| AU2018358157B2 (en) | 2017-11-02 | 2023-03-09 | Abbvie Inc. | Modulators of the integrated stress pathway |
| JP2021501785A (ja) | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| CA3080948A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| UY37956A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| SG11202004009TA (en) | 2017-11-02 | 2020-05-28 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| WO2019090078A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| AU2018383675A1 (en) | 2017-12-13 | 2020-07-09 | Altos Labs, Inc. | Inhibitors of integrated stress response pathway |
| EP3768660A1 (en) | 2018-03-23 | 2021-01-27 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
| EP3820843A1 (en) | 2018-07-09 | 2021-05-19 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds |
| WO2020031107A1 (en) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| TWI771621B (zh) | 2018-10-11 | 2022-07-21 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| EP3923935A4 (en) | 2019-02-13 | 2022-10-26 | Denali Therapeutics Inc. | COMPOUNDS, COMPOSITIONS AND METHODS |
| MA54959A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| WO2020181247A1 (en) | 2019-03-06 | 2020-09-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| PE20220572A1 (es) | 2019-04-30 | 2022-04-20 | Calico Life Sciences Llc | Moduladores de la via integrada del estres |
| EP3962899A1 (en) | 2019-04-30 | 2022-03-09 | Calico Life Sciences LLC | Substituted cyclolakyls as modulators of the integrated stress pathway |
| US20240059662A1 (en) | 2020-12-18 | 2024-02-22 | Denali Therapeutics Inc. | Solid forms of a compound |
-
2018
- 2018-08-08 CR CR20200054A patent/CR20200054A/es unknown
- 2018-08-08 CN CN202410183135.XA patent/CN118239937A/zh active Pending
- 2018-08-08 MX MX2020001352A patent/MX2020001352A/es unknown
- 2018-08-08 WO PCT/US2018/045868 patent/WO2019032743A1/en not_active Ceased
- 2018-08-08 IL IL272089A patent/IL272089B2/en unknown
- 2018-08-08 PH PH1/2020/550028A patent/PH12020550028B1/en unknown
- 2018-08-08 AU AU2018313850A patent/AU2018313850B2/en active Active
- 2018-08-08 EP EP18844666.0A patent/EP3665156A4/en active Pending
- 2018-08-08 MA MA049858A patent/MA49858A/fr unknown
- 2018-08-08 CA CA3071024A patent/CA3071024A1/en active Pending
- 2018-08-08 CN CN201880055607.6A patent/CN111094233B/zh active Active
- 2018-08-08 MY MYPI2020000561A patent/MY201438A/en unknown
- 2018-08-08 SG SG11202000532SA patent/SG11202000532SA/en unknown
- 2018-08-08 KR KR1020207005952A patent/KR102757890B1/ko active Active
- 2018-08-08 CN CN202410187269.9A patent/CN118239938A/zh active Pending
- 2018-08-08 IL IL301709A patent/IL301709B2/en unknown
- 2018-08-08 JP JP2020505383A patent/JP2020530446A/ja not_active Withdrawn
- 2018-08-08 US US16/637,718 patent/US11236100B2/en active Active
- 2018-08-08 KR KR1020257001611A patent/KR20250017299A/ko active Pending
- 2018-08-08 PE PE2020000174A patent/PE20200834A1/es unknown
- 2018-08-09 TW TW107127864A patent/TW201920115A/zh unknown
-
2020
- 2020-01-31 MX MX2023003989A patent/MX2023003989A/es unknown
- 2020-02-02 SA SA520411222A patent/SA520411222B1/ar unknown
- 2020-02-03 CO CONC2020/0001220A patent/CO2020001220A2/es unknown
- 2020-02-03 CL CL2020000299A patent/CL2020000299A1/es unknown
-
2021
- 2021-11-19 US US17/531,039 patent/US11851440B2/en active Active
-
2022
- 2022-12-28 JP JP2022211691A patent/JP2023052166A/ja not_active Withdrawn
-
2023
- 2023-03-22 AU AU2023201775A patent/AU2023201775A1/en not_active Abandoned
-
2024
- 2024-12-19 JP JP2024223976A patent/JP2025031810A/ja active Pending
-
2025
- 2025-01-08 US US19/014,044 patent/US20250388595A1/en active Pending
- 2025-01-31 AU AU2025200658A patent/AU2025200658A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11795164B2 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| TWI724079B (zh) | 可溶性鳥苷酸環化酶刺激劑 | |
| JP2020532506A5 (enExample) | ||
| JP5728487B2 (ja) | 三環式ヘテロ環化合物 | |
| US20100280082A1 (en) | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | |
| US11254663B2 (en) | Substituted bicyclic compounds as farnesoid X receptor modulators | |
| JP2017193592A5 (enExample) | ||
| JP5602230B2 (ja) | スフィンゴシン−１−リン酸受容体アゴニスト | |
| JP2009525340A5 (enExample) | ||
| JP2018529745A (ja) | Ｎｒｆ２レギュレーターとしてのビアリールピラゾール | |
| WO2013192125A1 (en) | Pyrazolyl derivatives as syk inhibitors | |
| JP2012515789A (ja) | スフィンゴシン−１−リン酸アゴニストとしてのピラゾール−１，２，４−オキサジアゾール誘導体 | |
| JP2016516737A (ja) | 新規ピリジン誘導体 | |
| JP2021535137A5 (enExample) | ||
| JP2017523223A5 (enExample) | ||
| JP2014525467A (ja) | Ｐｄｅ１０モジュレーター | |
| JP2020520925A5 (enExample) | ||
| JP2024536039A5 (enExample) | ||
| WO2015155566A1 (en) | Fused pyrazole compounds as cb1r antagonists and uses thereof | |
| EA047337B1 (ru) | Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора | |
| TW202409010A (zh) | 人類呼吸道融合病毒及人類間質肺炎病毒之抑制劑 | |
| HK1255028B (en) | 4-amino-2-(1h-pyrazolo[3,4-b]pyridin-3-yl)-6-oxo-6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidine derivatives and the respective (1h-indazol-3-yl) derivatives as cgmp modulators for treating cardiovascular diseases |